← All indications
Lymphoma, B-Cell, Marginal Zone
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
Drugs by status
Approved for this indication (1)
Phase 3 trials (24)
Phase 2 trials (104)
- 131i-rituximab
- allopurinol
- cladribine
- sd-101
- thalidomide
- methylprednisolone
- ibritumomab tiuxetan
- acalabrutinib
- alx148
- atezolizumab
- urea
- venetoclax
- brentuximab vedotin
- bryostatin
- busulfan
- carfilzomib
- temsirolimus
- cirmtuzumab
- clofarabine
- Iopofosine
- nelarabine
- polatuzumab vedotin
- doxycycline
- selinexor
- eltrombopag
- entospletinib
- n-(4-hydroxyphenyl)all-trans retinamide
- gemcitabine
- oblimersen sodium
- tacrolimus
- +74 more
Phase 1 trials (94)
- di-leu16-il2
- fau
- decitabine
- allogeneic natural killer cells
- alvespimycin
- apolizumab
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- sorafenib
- belinostat
- blinatumomab
- bms-986178
- irinotecan
- cdx-301
- cilengitide
- devimistat
- entinostat
- genetically engineered lymphocyte therapy
- paclitaxel
- imatinib
- gs-9901
- ar-42
- aldesleukin
- immu-114
- in111 anti-cd45 monoclonal antibody bc8
- ispinesib
- ly3214996
- methoxyamine
- morab-004
- voruciclib
- pevonedistat
- +64 more
Organizations
Organization Involved with Phase 3 Indications (18)
- Incyte
- Pharmacyclics
- Biocad
- Sponsor GmbH
- Verastem, Inc.
- National Institutes of Health (NIH)
- French Innovative Leukemia Organisation
- French Study Group on Chronic Lymphoid Leukemia
- Polish Lymphoma Research Group
- Justus Liebig University Giessen
- University of Milan
- University of Rochester
- International Extranodal Lymphoma Study Group
- University of Lyon
- The Lymphoma Study Association
- University of Barcelona
- Moorgreen Hospital, Southampton
- Memorial Sloan-Kettering Cancer Center
Organization Involved with Phase 2 Indications (107)
- AbbVie
- Seattle Genetics
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Roche
- Gilead Sciences
- AstraZeneca
- Merck
- Eli Lilly
- Genentech
- Biogen
- BeOne Medicines
- Beijing Mabworks Biotech Co., Ltd.
- GlaxoSmithKline
- Innovent Biologics (Suzhou) Co. Ltd.
- Kite Pharma, Inc.
- Lipomed
- Sunesis Pharmaceuticals
- TG Therapeutics, Inc.
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- University of Pennsylvania
- Academic and Community Cancer Research United
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Case Western Reserve University
- Cornell University
- Harvard University
- Dong-A University
- +77 more
Organization Involved with Phase 1 Indications (26)
- Spectrum Pharmaceuticals
- Immunomedics
- Morphotek
- Novartis
- Arno Therapeutics
- ArQule
- Celldex Therapeutics
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- University of Pittsburgh
- AIDS Malignancy Consortium
- Anhui Medical University
- Brown University
- Cancer and Leukemia Group B (CALGB)
- Johns Hopkins University
- Rhode Island Hospital
- Southwest Oncology Group
- University of South Florida
- University of Toronto
- Wake Forest University
- University of California, Davis
- MEI Pharma
- University of Wisconsin
- Clinipace LTD
- Damon Runyon Cancer Research Foundation
- OHSU Knight Cancer Institute
- IGM Biosciences, Inc.
Organization Involved with Other Experimental Indications (7)